Slide 1: Q1 2026 Results
May 1, 2026 Q1 2026 Results Stephan B. Tanda, Aptar President and CEO Vanessa Kanu, Executive Vice President and CFO
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q1 2026 Financial Highlights
Q1 2026 Financial Highlights First Quarter 2026 Highlights: 11% Q1 Core Sales* were flat • Continue to see growing demand in key areas including Q1 Reported Sales compared to the GLP-1 therapies, biologics, systemic nasal drug delivery, Growth prior year nasal decongestants, ophthalmic dispensing, a
Slide 4: Recent Product and Technology Highlights
Recent Product and Technology Highlights Pharma Beauty Closures Unidose Powder neffy® approved by Partnership with Patented Dual Inverted, Tab Top Prestige Prestige Nasal Delivery Health Canada and Enable Injections for Pump Technology Lidless Dispensing Fragrance Pump Fragrance Pump System for ENA
Slide 5: First Quarter 2026 Reported Results
First Quarter 2026 Reported Results Q1 Reported Sales Q1 Reported EPS (in millions $) $1,200 $1.40 $983 $1.20 $1.17 -4% $1.12 $1,000 $887 11% $1.00 $800 $0.80 $600 $0.60 $400 $0.40 $200 $0.20 $- $- Q1 2025 Q1 2026 Q1 2025 Q1 2026 +8% 25.8% 22.4% Flat Currency Effects Q1 2025 Q1 2026 Core Reported Re
Slide 6: First Quarter 2026 Adj. EPS and Adj. EBITDA
First Quarter 2026 Adj. EPS and Adj. EBITDA Q1 Adjusted EPS* Q1 Adjusted EBITDA* (in millions $) $1.60 $240 $1.40 $1.30 -8% $1.19 $200 $183 3% $189 $1.20 $160 $1.00 $0.80 $120 $0.60 $80 $0.40 $0.20 $40 $- $- Q1 2025 Q1 2026 Q1 2025 Q1 2026 25.8% 22.6% Q1 2025 Q1 2026 Effective Tax Effective Tax Rate
Slide 7: Pharma First Quarter 2026 Results
Pharma First Quarter 2026 Results Q1 2026 Core Sales* by Market Q1 Sales (in millions $) Adjusted EBITDA Margin % $500 40% • Prescription core sales decreased 10% $450 $439 34.8% $409 33.3% • Consumer Healthcare core sales increased $400 4% Reported 30% $350 7% • Injectables core sales increased 20%
Slide 8: Beauty First Quarter 2026 Results
Beauty First Quarter 2026 Results Q1 2026 Core Sales* by Market Q1 Sales (in millions $) Adjusted EBITDA Margin % $400 $364 14% • Fragrance, Facial Skincare and $360 12.1% Color Cosmetics (F&F) core sales $320 $306 12% 11.1% increased 3% $280 Reported 10% • Personal Care core sales increased 19% 6%
Slide 9: Closures First Quarter 2026 Results
Closures First Quarter 2026 Results Q1 2026 Core Sales* by Market Q1 Sales (in millions $) Adjusted EBITDA Margin % $200 18% $181 • Food core sales decreased 3% $180 $172 15.8% 16% • Beverage core sales increased 10% $160 Reported 14% 13.1% $140 5% 12% $120 Core 10% YTD 2026 Percentage of Sales by M
Slide 10: Outlook
Outlook Earnings Per Share Outlook Highlights $1.80 $1.67 $1.67 • Looking ahead to Q2, excluding destocking in $1.60 emergency medicine within Pharma, Aptar anticipates a $1.32 – $1.40 solid quarter with growth across each segment $1.40 $1.20 • Outside of the emergency medicine end market, $1.00 Apt
Slide 11: Key Highlights for Q2 / FY2026
Key Highlights for Q2 / FY2026 Quarterly (Expected) Effective Tax Rate 22.5% to 24.5% for Q2 2026 Prior year Q2 comparable adjusted effective tax rate = 20% Currency Guidance (Euro) 1.18 for Q2 2026 Assuming a Euro to USD Exchange Rate Full Year (Expected) CapEx Range for Full Year 2026 $260 to $280
Slide 12: Appendix
Aptar.4 Appendix
Slide 13: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 13
Slide 14: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data) 14
Slide 15: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands, Except Per Share Data) 15
Slide 16: Reconciliation of Reported to Core Sales Growth by Market
Reconciliation of Reported to Core Sales Growth by Market (Rounded to the nearest whole percent) 16
Slide 17: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 17
Slide 18: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 18
Slide 19: Reconciliation of Adjusted EBIT After Taxes to Net Income
Reconciliation of Adjusted EBIT After Taxes to Net Income (Unaudited) ($ In Thousands) 19
Slide 20: Reconciliation of Capital to Stockholders' Equity
Reconciliation of Capital to Stockholders’ Equity (Unaudited) ($ In Thousands) 20
Slide 21: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 21
Slide 22: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 22
Slide 23: Supplemental Information
Supplemental Information 23
Slide 24: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 24